ADGRB1, also known as brain angiogenesis inhibitor 1 (BAI1), belongs to GPCR and is involved in multiple cancer development.[8, 38, 39, 40, 41] ADGRB1 has been reported to have antiangiogenic effects, and suppressing ADGRB1 by MBD2 leads to tumor growth in glioblastoma.[40, 42] In medulloblastoma and T‐cell acute lymphoblastic leukemia, the interaction between ADGRB1 and MDM2 prevents MDM2‐mediated p53 polyubiquitination,[8, 41] which is consistent with our findings in ICC. Here, MBD2 is linked to intrahepatic cholangiocarcinoma.